Abstract
We have generated a new transgenic mouse model of Type 1 Diabetes (T1D) in which mouse Major Histocompatibility Complex-II (MHC-II) molecules were replaced with human DQ8 in all antigen-presenting cells. Our mice also express human Glutamic Acid Decarboxylase, isoform 65 (GAD65) in pancreatic beta cells as humans do. Our humanized mouse-model has the closest known phenotype to human T1D and is most suitable for addressing pathophysiology and treatment of the disease. To that end, we have developed pancreatic beta-cell, antigen-specific, Chimeric Antigen Receptor (CAR) T regulatory cells (Tregs) and explored their therapeutic potential against T1D. Ours is the first report of a successful, antigen-specific CAR-Treg treatment of T1D in a new model that closely resembles the human disease. Conceivably, treatment with antigen-specific CAR-Tregs will allow for recovery and reconstitution of beta cells in humans as well.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
